BioTime has entered into a research and option agreement with Orbit Biomedical regarding technology to deliver OpRegen to treat dry age-related macular degeneration, according to a press release.Under the terms of the exclusive 12-month agreement, the …
Author: Healio ophthalmology
Woman presents with decreased night vision
A 56-year-old Caucasian woman was referred from an outside office to the Neuro-ophthalmology service at the New England Eye Center for evaluation of decreased night vision. Her symptoms started about 2 months before her presentation, when she noticed s…
Well-trained pediatric optometrists can help fill access gaps
Incorporating well-trained pediatric optometrists into pediatric ophthalmology practices has helped expand primary pediatric eye care services to children, often closing gaps in access to this often routine but nonetheless important service.An American…
Swept-source OCT: A new frontier in study and management of choroidal disorders
Swept-source OCT with the Topcon DRI Triton system provides high-resolution imaging of the choroid, allowing visualization of previously unknown disease manifestations, according to one researcher. The combination of high speed and longer wavelength en…
Vital dyes necessary for vitreomacular surgery but may have risks
Vital dyes are used by vitreoretinal specialists to visualize transparent preretinal tissues, to enhance identification and to remove transparent anatomical layers during vitreoretinal surgery, but the dyes can result in irreversible acute toxicity in …
Steroids and NSAIDs can be synergistic
Steroids and NSAIDs in drop form are used by cataract surgeons to reduce inflammation and pain after cataract and other ocular surgery. In the most common study protocol used for FDA approval in the United States, both pain and inflammation are graded …
New drugs, protocols reduce pain and inflammation associated with cataract surgery
Drugs, better surgical techniques and new technologies can limit the amount of pain and inflammation a patient experiences after undergoing cataract surgery.Ophthalmologists and patients have different views about what constitutes a successful cataract…
Presenting ‘premium’ pricing to the patient: A package deal or a la carte
Welcome to another edition of CEDARS/ASPENS Debates. CEDARS/ASPENS is a joint society of cornea, cataract and refractive surgery specialists, here to discuss some of the latest hot topics in ophthalmology.As cataract surgery technology has gained unpre…
Managing IOP issues after cataract surgery
It is recognized that cataract surgery can help lower IOP, likely due to the increased angle opening permitted by the thin IOL as compared with the much thicker cataractous lens. But there can be fluctuations in the IOP after cataract surgery, and thes…
Intraoperative floppy iris syndrome may be possible after DMEK
Intraoperative floppy iris syndrome is a well-known and highly feared entity. By some measures, it is the most common difficulty encountered during cataract surgery and a significant risk factor for severe intraoperative complications, including poster…
How do you balance cost of postoperative steroids and NSAIDs and still keep pace with innovative medications?
Click here to read the Cover Story to this Point/Counter.For cataract surgery, we use Pred-Gati-Brom (prednisolone acetate, gatifloxacin, bromfenac) from Imprimis. If the patient is upgrading in any way, including limbal relaxing incisions, the drop is…
DREAM: Fish oil works
The jury has returned, and the verdict is in: If you treat dry eye disease with a protocol that includes purified fish oil, your patients will feel better. Seriously. It says so right there in the results section of the DREAM study. Patients with sever…
Gemini to initiate CLARITY dry AMD disease registry and study
Gemini Therapeutics announced a disease registry and natural history study to identify and characterize disease progression in patients with non-central geographic atrophy secondary to dry age-related macular degeneration, according to a press release….
Inveltys now available in US
Kala Pharmaceuticals has launched its twice-daily ocular corticosteroid Inveltys in the United States, according to a press release.Inveltys (loteprednol etabonate ophthalmic suspension 1%), which uses Kala’s Ampplify mucus-penetrating particle drug de…
Netarsudil ophthalmic solution shows positive phase 2 results in Japanese-American population
A pilot phase 2 trial showed Aerie Pharmaceuticals’ netarsudil ophthalmic solution lowered IOP in a Japanese-American population, according to a press release.Two dose concentrations of netarsudil ophthalmic solution, known as Rhopressa (netarsudil oph…
Bimatoprost sustained-release implant reduces IOP in phase 3 study
A bimatoprost sustained-release implant reduced IOP by approximately 30% over 12 weeks in a second phase 3 study, Allergan announced in a press release.The majority of patients with open-angle glaucoma or ocular hypertension in the 528-subject trial we…
VIDEO: State of the art of intracameral antibiotics and steroids: Drop-free cataract surgery
NEW YORK — From OSN New York 2018, M. Stewart Galloway, MD, of Cumberland Eye Care in Crossville, Tennessee, gives his presentation on the state of the art of intracameral antibiotics and steroids.
VIDEO: Presbyopia correction in the post-corneal refractive surgery patient
NEW YORK — From OSN New York 2018, Kathryn M. Hatch, MD, director of refractive surgery at Massachusetts Eye and Ear, gives her presentation on presbyopia correction in the post-corneal refractive surgery patient.
Laser-induced chorioretinal anastomosis can lessen CRVO treatment burden
Adding laser-induced chorioretinal anastomosis to anti-VEGF treatment for central retinal vein occlusion can reduce the number of injections needed, according to a study.A randomized clinical trial included 58 patients with macular edema caused by CRVO…
EyePoint plans accelerated Dexycu launch
EyePoint Pharmaceuticals will launch both Dexycu and Yutiq in the first quarter, the company announced in a press release.The two drugs were approved in 2018, and while the company originally planned to launch Yutiq (fluocinolone acetonide intravitreal…